February 10, 2014
Sepsis is a generalized and exacerbated inflammatory reaction caused by a serious infection that could lead to multi-organ failure, shock and often death (30-50 % of cases). Increased antibiotic resistance, together with the fact that these drugs combat groups of bacteria but not the proinflammatory activity caused by them or their toxins, makes sepsis a disease orphan of effective therapies. A study published in the Journal of Infectious Diseases shows that CD6, a molecule from our own lymphocytes, could be an effective alternative or complement for antibiotics in cases of sepsis by both Gram-positive and Gram-negative bacteria, regardless they are resistant to antibiotics or producing lethal toxins. The work is the result of a academia-industry collaboration between the team led by Dr. Francisco Lozano, Senior Consultant at the Immunology Service of the Hospital Clínic and head of the IDIBAPS research team Immune receptors of the innate and adaptive system and at the University Barcelona, together with members of the R&D team at ImmunNovative Developments SL, a recently created spin-off which emerged based on patents generated by the aforementioned research group. The first authors of the study are Mario Martínez-Florensa and Marta Consuegra-Fernández.